Please assess the completion status of the following clinical trial:

Trial Title: Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~•Healthy participants~* Deemed to be in good general health by history and physical examination~  •Resident of Guanacaste Province of Costa Rica and surrounding areas~* Must remain a resident for ≥ 6 months after the first study vaccination~PATIENT CHARACTERISTICS:~Age~* 18 to 25~Performance status~•Not specified~Life expectancy~•Not specified~Hematopoietic~•Not specified~Hepatic~* No history of chronic hepatitis requiring treatment~* No acute or chronic clinically significant hepatic function abnormality by physical examination or laboratory findings~* No known history of hepatitis A infection~Renal~* No history of kidney disease requiring treatment~* No acute or chronic clinically significant kidney function abnormality by physical examination or laboratory findings~Cardiovascular~* No acute or chronic clinically significant cardiovascular function abnormality by physical examination or laboratory findings Pulmonary~* No acute or chronic clinically significant pulmonary function abnormality by physical examination or laboratory findings Immunology~* No history of allergic disease~* No history of autoimmune disorder requiring treatment~* No history of allergic reaction (e.g., difficulty breathing) to any vaccine~* No suspected allergy or reaction likely to be exacerbated by a component of the study vaccines (e.g., 2-phenoxyethanol or neomycin)~* No hypersensitivity to latex~* No diagnosis or suspicion of any immunodeficient condition by medical history or physical examination Other~* Not pregnant or nursing~  ◦No delivery within the past 3 months~* Negative pregnancy test~* Fertile patients must use effective contraception for 30 days before, during, and for 60 days after completion of study treatment~* Able to speak or understand Spanish~* Mentally competent~* Able to undergo pelvic exam (i.e., no heavy bleeding \[menstruation or otherwise\] or heavy vaginal discharge)~* No history of cancer requiring treatment~* No history of diabetes requiring treatment~* No history of other chronic conditions requiring treatment~* No acute or chronic clinically significant neurologic function abnormality by physical examination or laboratory findings~* No other acute disease~* No fever ≥ 37.5º C~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 6 months since prior chronic administration (i.e., \> 14 days) of immune-modulating drugs~* More than 90 days since prior immunoglobulins~* More than 30 days since prior and no other concurrent investigational or non-registered vaccines~* More than 30 days since prior registered vaccines~* More than 8 days since prior routine meningococcal, hepatitis B, influenza, or diphtheria/tetanus vaccine~* No prior vaccination against hepatitis A~* No prior vaccination against human papillomavirus~* No prior monophosphoryl lipid A or AS04 adjuvant~Chemotherapy~•Not specified~Endocrine therapy~* More than 6 months since prior chronic administration (i.e., \> 14 days) of corticosteroids (e.g., ≥ 0.5 mg/kg/day of prednisone or equivalent)~* Concurrent inhaled or topical steroids allowed~Radiotherapy~•Not specified~Surgery~•No prior hysterectomy~Other~* More than 6 months since prior chronic administration (i.e., \> 14 days) of immunosuppressants~* More than 30 days since prior and no other concurrent investigational or non-registered drugs

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Cervarix Group (Type: EXPERIMENTAL): Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.
- Havrix Group (Type: ACTIVE_COMPARATOR): Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).